

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on May 21, 2025

Relypsa

RRID:SCR_004047

Type: Tool

Proper Citation

Relypsa (RRID:SCR_004047)

Resource Information

URL: <http://www.relypsa.com/>

Proper Citation: Relypsa (RRID:SCR_004047)

Description: Biopharmaceutical company focused on development and commercialization of non-absorbed polymeric drugs to treat disorders in areas of renal, cardiovascular and metabolic diseases. February 2021 - Relypsa changed its name to Vifor Pharma. Company is focused on development and commercialization of late stage medicines that will change treatment paradigms and improve patients lives.

Abbreviations: RLYP

Synonyms: Relypsa Inc., Vifor Pharma

Resource Type: commercial organization

Keywords: biopharmaceutical, pharmaceutical, drug, late stage medicines, late stage medicines commercialization, late stage medicines development

Funding:

Resource Name: Relypsa

Resource ID: SCR_004047

Alternate IDs: nlx_158475

Record Creation Time: 20220129T080222+0000

Record Last Update: 20250519T203320+0000

Ratings and Alerts

No rating or validation information has been found for Relypsa.

No alerts have been found for Relypsa.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We have not found any literature mentions for this resource.